Seven Eight Capital’s Horizon Therapeutics Public Limited Company Ordinary Shares HZNP Stock Holding History

Seven Eight Capital’s Portfolio HZNP Stock Details HZNP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-13,000	Closed	-$385K	–	634
2020 Q1	$385K	Buy	+13,000	New	+$440K	0.1%	264
2019 Q4	–	Sell	-55,020	Closed	-$1.5M	–	821
2019 Q3	$1.5M	Buy	+55,020	New	+$1.42M	0.08%	357
2019 Q2	–	Sell	-156,299	Closed	-$4.13M	–	807
2019 Q1	$4.13M	Buy	156,299 +92,500	+145%	+$2.19M	0.22%	143
2018 Q4	$1.25M	Sell	63,799 -24,064	-27%	-$472K	0.07%	326
2018 Q3	$1.72M	Buy	+87,863	New	+$1.67M	0.1%	278
2017 Q1	–	Sell	-93,094	Closed	-$1.51M	–	744
2016 Q4	$1.51M	Buy	93,094 +44,400	+91%	+$805K	0.3%	113
2016 Q3	$883K	Buy	+48,694	New	+$951K	0.26%	147
2016 Q2	–	Sell	-1,494	Closed	-$25K	–	725
2016 Q1	$25K	Buy	+1,494	New	+$26.1K	0.01%	469
2014 Q3	–	Sell	-100	Closed	-$2K	–	728
2014 Q2	$2K	Buy	+100	New	+$1.43K	﹤0.01%	492

Other funds holding HZNP

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Janus Henderson Group London $209B AUM 37.72% 1-Year Est. Return

William Blair Investment Management Chicago, Illinois $33.3B AUM 44.76% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Paulson & Co New York $2.58B AUM 68.51% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return

JP Morgan Chase New York $1.81T AUM 41.13% 1-Year Est. Return

Citadel Advisors Miami, Florida $875B AUM 40.89% 1-Year Est. Return

Seven Eight Capital's HZNP Position: Q2 2020 in Review

Seven Eight Capital sold out of Horizon Therapeutics Public Limited Company Ordinary Shares (HZNP) in Q2 2020, closing a stake of 13,000 shares — an estimated $385K sold.

Seven Eight Capital first reported a position in HZNP in Q2 2014 and held it in 9 quarters. The position peaked at $4.13M in Q1 2019. 354 funds tracked by Wall St. Rank hold HZNP as of Q2 2020.

Seven Eight Capital reported no remaining Horizon Therapeutics Public Limited Company Ordinary Shares position as of Q2 2020 after selling out during the quarter.
Seven Eight Capital sold 13,000 Horizon Therapeutics Public Limited Company Ordinary Shares shares in Q2 2020, an estimated $385K.
Seven Eight Capital first reported a position in Horizon Therapeutics Public Limited Company Ordinary Shares in Q2 2014 and held it in 9 quarters.
Seven Eight Capital's Horizon Therapeutics Public Limited Company Ordinary Shares position peaked at $4.13M in Q1 2019.
354 funds tracked by Wall St. Rank held Horizon Therapeutics Public Limited Company Ordinary Shares as of Q2 2020.

Based on Seven Eight Capital's 13F filing for Q2 2020, filed 6 Aug 2020.